Zelira Therapeutics ZLDAF Stock
Zelira Therapeutics Price Chart
Zelira Therapeutics ZLDAF Financial and Trading Overview
| Zelira Therapeutics stock price | 0.35 USD |
| Previous Close | 0.35 USD |
| Open | 0.21 USD |
| Bid | 0.32 USD x 500000 |
| Ask | 0.38 USD x 250000 |
| Day's Range | 0.21 - 0.21 USD |
| 52 Week Range | 0.2 - 0.42 USD |
| Volume | 5K USD |
| Avg. Volume | 21 USD |
| Market Cap | 4.83M USD |
| Beta (5Y Monthly) | 0.556 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.23 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ZLDAF Valuation Measures
| Enterprise Value | 6.47M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 7370.215 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 9862.633 |
| Enterprise Value/EBITDA | -1.55 |
Trading Information
Zelira Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.556 |
| 52-Week Change | 58.44% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 0.42 USD |
| 52 Week Low | 0.2 USD |
| 50-Day Moving Average | 0.34 USD |
| 200-Day Moving Average | 0.3 USD |
ZLDAF Share Statistics
| Avg. Volume (3 month) | 21 USD |
| Avg. Daily Volume (10-Days) | 0 USD |
| Shares Outstanding | 11.9M |
| Float | 6.64M |
| Short Ratio | N/A |
| % Held by Insiders | 52.15% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:175 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2025 |
| Most Recent Quarter (mrq) | June 30, 2025 |
| Next Fiscal Year End | June 30, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -658713.13% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -83.30% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 656 USD |
| Revenue Per Share (ttm) | 0 USD |
| Quarterly Revenue Growth (yoy) | -100.00000000000000000000000000000000% |
| Gross Profit (ttm) | -802945 USD |
| EBITDA | -4174106 USD |
| Net Income Avi to Common (ttm) | -3627872 USD |
| Diluted EPS (ttm) | -0.23 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 5.66K USD |
| Total Cash Per Share (mrq) | 0 USD |
| Total Debt (mrq) | 2.14M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.11 |
| Book Value Per Share (mrq) | -0.27051 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -4906854 USD |
| Levered Free Cash Flow (ttm) | -764668 USD |
Profile of Zelira Therapeutics
| Country | United States |
| State | WA |
| City | Perth |
| Address | 101 St Georges Terrace |
| ZIP | 6000 |
| Phone | 61 8 6558 0886 |
| Website | https://zeliratx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter (OTC) products, including SprinJeneCBD, an oral care product; and acne treatment products under the RAF FIVE name, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. In addition, it offers products for autism and chronic noncancer pain. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is based in Perth, Australia.
Q&A For Zelira Therapeutics Stock
What is a current ZLDAF stock price?
Zelira Therapeutics ZLDAF stock price today per share is 0.35 USD.
How to purchase Zelira Therapeutics stock?
You can buy ZLDAF shares on the OTC Markets OTCQB exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Zelira Therapeutics?
The stock symbol or ticker of Zelira Therapeutics is ZLDAF.
Which industry does the Zelira Therapeutics company belong to?
The Zelira Therapeutics industry is Biotechnology.
How many shares does Zelira Therapeutics have in circulation?
The max supply of Zelira Therapeutics shares is 13.81M.
What is Zelira Therapeutics Price to Earnings Ratio (PE Ratio)?
Zelira Therapeutics PE Ratio is now.
What was Zelira Therapeutics earnings per share over the trailing 12 months (TTM)?
Zelira Therapeutics EPS is -0.23 USD over the trailing 12 months.
Which sector does the Zelira Therapeutics company belong to?
The Zelira Therapeutics sector is Healthcare.